

INTRODUCTION

R&D MEETING 2016



Yoshihiko Hatanaka
President and CEO
Astellas Pharma Inc.
December 8, 2016

ACHIEVING SUSTAINABLE GROWTH

Strategic Priorities –Strategic Plan 2015-2017

Maximizing the Product Value

Creating Innovation

- Enhancing Capabilities to Deliver Innovative Medicines
- Advancing into New Opportunities

Pursuing Operational Excellence

Achievements since FY2015

Launch



Development progress

6 approvals for NDA/sNDAs*¹
8 NDA/sNDAs*¹
8 Phase 3 entries

Acquisition



*²

Research collaboration

Multiple collaborations in focused research area




*¹ NDA/sNDA in each region of US, EMEA and Japan

*² Transaction announced, completion pending

CREATE INNOVATION WITH EVOLVING FOCUS

*Turn innovative science
into value for patients
on the forefront of healthcare change*



CURRENT FOCUS AREAS

Core technologies

New technologies, new modalities

Existing TAs




Oncology

Urology

Immunology

Nephrology

Neuroscience



New TAs

Muscle Diseases

Ophthalmology

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.